Clinical Research Directory

Inclusion Criteria: * First recurrence of high-grade glioma for which surgical resection is not planned * Eligible tumor type, including Grade 3 or Grade 4 astrocytoma, Grade 3 oligodendroglioma, glioblastoma, or diffuse hemispheric glioma, with histologic confirmation of malignancy * Received prior standard treatment for high-grade glioma, including surgery followed by radiation alone or radiation with temozolomide * A single tumor located above the tentorium that is accessible for treatment with SRN-101 and is 1 to 4 centimeters in diameter * Karnofsky performance status of at least 70% * Life expectancy of at least 3 months * Recovered from the acute effects of prior anti-cancer treatment and meets required waiting periods following prior chemotherapy, radiation therapy, and major surgery * Adequate bone marrow, kidney, liver, and blood-clotting function * Willing to participate in the long-term safety follow-up study Exclusion Criteria: * Disseminated or multifocal disease * Pregnant or breastfeeding * History of or current liver disease, including active hepatitis B or hepatitis C, or human immunodeficiency virus * Receiving another tumor immunotherapy * Recent initiation or increase in systemic immunosuppressive therapy, including corticosteroids, except as permitted by the protocol * Recent neurologic dysfunction or abnormality that, in the Investigator's judgment, would prevent participation * Unable to comply with the study's safety monitoring requirements * Other medical conditions that, in the Investigator's judgment, could negatively affect the participant's ability to benefit from or tolerate the study * Unable to undergo magnetic resonance imaging (MRI)